Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of hyperproliferative dermatological diseases. Additionally we are shipping Retinoic Acid Receptor Responder (Tazarotene Induced) 3 Proteins (4) and Retinoic Acid Receptor Responder (Tazarotene Induced) 3 Kits (1) and many more products for this protein.
Showing 10 out of 77 products:
The current study establishes that hypoxia can profoundly influence the inducible RIG-I (show DDX58 Antibodies) protein expression in malignant cells of both human and murine origin, whereas this phenomenon was not identified in nonmalignant cell lines or primary cells.
our study demonstrates that the novel pathway lncRNA Ftx/miR (show MLXIP Antibodies)-545/RIG-I (show DDX58 Antibodies) promotes hepatocellular carcinoma development
this review describes antiviral activities of RIG-I (show DDX58 Antibodies) against influenza viruses (standing on three legs)
Study uncovered a novel aspect of Rig-I (show DDX58 Antibodies) in monitoring gut (show GUSB Antibodies) microbiota through regulating IgA (show IgA Antibodies) and IL6 (show IL6 Antibodies)-STAT3 (show STAT3 Antibodies)-dependent Reg3gamma pathway. Besides, Rig-I (show DDX58 Antibodies) loss could also promote colorectal cancer progression both in the presence and absence of intestinal bacteria.
this study indicated that increased expression of TIG3 in primary glioblastoma is a novel biomarker for predicting poor outcome of patients. We then hypothesize that TIG3 may function in a different pattern in glioblastoma
Foot-and-mouth disease virus Viroporin 2B antagonizes RIG-I (show DDX58 Antibodies)-mediated antiviral effects by inhibition of its protein expression.
Overexpression of TIG3 suppresses tumor growth in hepatocellular carcinoma
miR (show MLXIP Antibodies)-34a is an antioncogene in multiple tumors, in this study, RIG-I (show DDX58 Antibodies) and miR (show MLXIP Antibodies)-34a suppressed cell growth, proliferation, migration, and invasion in cervical cancer cells in vitro. miR (show MLXIP Antibodies)-34a was validated as a new regulator of RIG-I (show DDX58 Antibodies) by binding to its 3' untranslated region and upregulating its expression level.
Letter: Interleukin-22 (show IL22 Antibodies) inhibits tazarotene-induced gene 3 expression in keratinocytes via MAPK (show MAPK1 Antibodies)-ERK1/2 and JAK2 (show JAK2 Antibodies)/STAT3 (show STAT3 Antibodies) signaling.
TRIM25 (show TRIM25 Antibodies) plays an additional role in RIG-I (show DDX58 Antibodies)/MDA5 (show IFIH1 Antibodies) signaling other than RIG-I (show DDX58 Antibodies) ubiquitination via activation of NF-kappaB (show NFKB1 Antibodies).
Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of hyperproliferative dermatological diseases. These effects are mediated by specific nuclear receptor proteins that are members of the steroid and thyroid hormone receptor superfamily of transcriptional regulators. RARRES1, RARRES2, and RARRES3 are genes whose expression is upregulated by the synthetic retinoid tazarotene. RARRES3 is thought act as a tumor suppressor or growth regulator.
retinoic acid receptor responder (tazarotene induced) 3
, retinoic acid receptor responder protein 3
, HRAS-like suppressor 4
, RAR-responsive protein TIG3
, retinoic acid-inducible gene 1
, retinoid-inducible gene 1 protein
, tazarotene-induced gene 3 protein